source Post navigation First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec's NLRP3 Inhibitor, Dapansutrile – PR Newswire People can reduce risk of death from diabetes by doing one common thing – The Mirror
